Leadership With Decades of Oncology Experience

Dr. Ramachandra is an experienced biopharmaceutical executive with a track record in building and scaling innovative healthcare companies. Prior to Lutris, he most recently served as Founder of SR Global Health, LLC, a healthcare advisory firm, and currently serves on the Board of Directors at Lyell Immunopharma (Nasdaq: LYEL). Previously, he was CEO and Board Director at ImmPACT Bio USA, leading its transformation into a clinical-stage cell therapy company and its acquisition by Lyell Immunopharma. Earlier, he held executive leadership roles at Baxter International (NYSE: BAX), where he led the global pharmaceutical business; Pfizer (NYSE: PFE); and Hospira (prior to its acquisition by Pfizer), overseeing global R&D across these companies and directed business development initiatives.

Dr. Ramachandra holds an B.A., M.D. and Ph.D. in Immuno-Oncology from Rutgers University, an MBA from The Wharton School, and is a named inventor on multiple patents. He was recognized by the Los Angeles Business Journal as one of the 100 Most Influential Leaders (2024–2025).

Dr. Goldberger holds a Ph.D. in cancer immunotherapy from the Weizmann Institute of Science and was post-doctoral fellow at Stanford University where he conducted research in systems immunology. He brings more than 10 years of experience in corporate development and business operations in the biotech and life science tools verticals where he held key positions at Instil Bio (NASDAQ:TIL), ImmPACT Bio (acquired by Lyell Immunopharma, NASDAQ:LYELL) and Standard Biotools (NASDAQ:LAB).

Dr. Benjamin is a hematologist/oncologist and former blood and marrow transplant faculty at Stanford University. Earned his Ph.D. at NYU and was a post-doctoral fellow at UCSF where he conducted research in lymphocyte development and signal transduction.

Dr. Benjamin served as CMO at ImmPACT Bio (acquired by Lyell Immunopharma, NASDAQ:LYELL) where he oversaw the medical, clinical operations, translational medicine, data management, and regulatory teams. Before joining ImmPACT, Dr. Benjamin was SVP at Atreca, a company dedicated to advancing patient-derived antibody therapeutics for solid tumors and infectious diseases. Prior to that, as Medical Director at Amgen, Dr. Benjamin helped secure global BLAs for blinatumomab, the first Bispecific T cell Engager.

Dr. Laura Millichamp qualified as a Pharmacist, before completing a PhD in the field of topical products. She was a Pharmaceutical Assessor at the MHRA for over 7 years, where she assessed Marketing Authorization Applications and Scientific Advice requests submitted through National and European procedures. Laura then moved into Consulting supporting companies at all stages of product development with strategic and technical advice relating to activities including IND/IMPD data generation and authoring, early access initiatives (PRIME/ODD applications), Scientific Advice procedures, Marketing Authorization Applications and Lifecycle Maintenance.

As a board certified toxicologist, Ms. Johnson has been assisting pharmaceutical companies with all phases of nonclinical development for more than 20 years. Activities include representing clients at FDA, negotiating nonclinical testing strategies, preparing INDs, NDAs, briefing documents, and monitoring studies. Prior to that she worked in agricultural and industrial chemical product registrations with EPA and litigation support work.